Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD

Journal of Medical Microbiology

Volumn 51, Issue 4, 2002, Pages 350-357

  Baghian, Abolghasem ^a   Chouljenko, Vladimir N ^a   D'Auvergne, Oswald ^a   Newman, Mark J ^a   Baghian, Salman ^a   Kousoulas, Konstantin G ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; DNA VACCINE; GLYCOPROTEIN B; GLYCOPROTEIN D; PLASMID VECTOR; PROTEIN ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG FORMULATION; EXPERIMENTAL MODEL; FEMALE; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RADIOIMMUNOPRECIPITATION; VIRUS GENE; VIRUS INFECTION;

EID: 0036201156     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-51-4-350     Document Type: Article

References (35)

1. The epidemiology and clinical manifestations of herpes simplex virus infections
2. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
3. Entry of alphaherpesviruses into cells
4. Membrane fusion induced by herpes simplex virus
5. Herpes simplex viruses and their replication
6. Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D
7. Expression of herpes simplex virus type 1 glycoprotein B in insect cells. Initial analysis of its biochemical and immunological properties
8. Native herpes simplex virus glycoprotein D vaccine: Immunogenicity and protection in animal models
9. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection
10. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D
11. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use
12. Protection from herpes simplex virus type I lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector
13. Placebo-controlled trail of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
14. Direct gene transfer into mouse muscle in vivo
15. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates
16. Immunization with plasmid DNA using a pneumatic gun
17. Bovine herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA
18. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA
19. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors
20. Heterologous protection against influenza by injection of DNA encoding a viral protein
21. Immune responses to nucleic acid vaccines to rabies virus
22. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody
23. DNA vaccines against malaria: Immunogenicity and protection in a rodent model
24. Introduction of mucosal immunity against herpes simplex virus by plasmid DNA immunization
25. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease
26. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs
27. DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection
28. Genetic vaccination against Coccidioides immitis: Comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA
29. Design and development of adjuvant-active nonionic block copolymers
30. Use of nonionic block copolymers in vaccines and therapeutics
31. Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly
32. Truncation of the carboxy-terminal 28 amino acids of glycoprotein B specified by herpes simplex virus type 1 mutant amb1511-7 causes extensive cell fusion
33. Synthesis and processing of glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system
34. High-efficiency transformation of mammalian cells by plasmid DNA
35. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes